Skin Cancer Clinical Trials
Melanoma
Learn More About Melanoma
For general information on melanoma (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| PTT-4256-01 | Melanoma | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| BI - 1456-0001 | Melanoma | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Immunotherapy | Genetically Modified Virus | Open - Recruiting | Boehringer Ingelheim | NCT05155332 | Enquire Now |
| SL-28-FIH | Melanoma | A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours | Immunotherapy | IV allogeneic, non-genetically modified cell-based therapy | Open - Recruiting | Second Life Therapeutics Pty Ltd. | ACTRN12625001342404p | Enquire Now |